Navigation Links
ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
Date:2/26/2008

growth in pancreatic and breast cancer models and recognizes CD9 on CD34+CD38- leukemic cancer stem cells." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3995:

"A monoclonal antibody targeting CD59 (AR36A36.11.1), enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusresearch.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ material
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
5. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
6. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
7. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
8. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
9. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. ARIUS to present at Chinese Global Financial Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... VILLAGE, Nev. , March 4, 2015 PDL BioPharma, ... the adjusted conversion rate for the: , 3.75% ... is 174.8506 shares of common stock per $1,000 principal amount ... The conversion rate for the note is adjusted in ... paid on March 12, 2015, to all stockholders who own shares ...
(Date:3/4/2015)... BALTIMORE , March 4, 2015 The ... of its 2015 Fellows in the Emerging Leaders in ... fostering future leaders in the field of biosecurity, UPMC ... biosecurity from a wide array of backgrounds, including biological ... private sector. "With the vision and ...
(Date:3/4/2015)... SANTA BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... regulatory consulting firm in the life sciences industry, hired ... Compliance. Blewitt leads the Cloud Compliance Services and ... sciences companies utilize cloud based applications while maintaining compliance ... 20 years, Blewitt has been an accomplished life sciences ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/jspg2c/global_biologics ) ... Biologics and Biosimilars Industry Report 2015" report ... Global Biologics and Biosimilars Industry Report 2015 is ... state of the biologics and biosimilars industry. ... the industry including definitions, classifications, applications and industry ...
Breaking Biology Technology:PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Global Biologics and Biosimilars Industry Report 2015-2020 2
... Market Opportunities for the Company,s Medical ... ... ), a biodefense company developing medical countermeasures,against biological and chemical threats, ... special UK government advisor., Lord Moonie will assist PharmAthene in ...
... China, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical Technology, Inc ... of plant extracts and pharmaceutical raw materials,for use ... it has signed a major supply agreement with ... Under the terms of the agreement Huifeng ...
... First Commercial Imaging Lab to Offer Quantitative Coronary Angiographic ... ... 11 ICON plc (NASDAQ: ICLR;,ISIN:IE0005711209), a global provider ... device industries, today,announced that its Medical Imaging division has ...
Cached Biology Technology:Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene 2Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene 3Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc. 2ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies 2
(Date:2/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... groundbreaking payment method. Payment accounts may be selected via ... accessed if both the speech (the word associated with ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... Lab has published recent findings that reveal some of the factors ... The paper, Stem Cell Aging is Controlled both Intrinsically ... 11 issue of Cell Stem Cell. Lei Pan, Predoctoral Researcher, and ... authors, respectively. It is ...
... base operations have left the U.S. Department of Defense (DOD) ... with highly toxic substances. University of Tennessee Research Professor ... awarded $1.3 million over three years to find the best ... keeping costs to a minimum. Parker is ...
... by Kevin Pope of Geo Eco Arc Research and ... the migration of anatomically modern humans out of Africa ... (BP). The comprehensive review of human genetic, ... the hypothesis, originally based largely on genetic evidence, that ...
Cached Biology News:Stowers Institute's Xie Lab demonstrates dual intrinsic and extrinsic control of stem cell aging 2UT researcher earns $1.3M grant to study toxic cleanup at DOD sites 2UT researcher earns $1.3M grant to study toxic cleanup at DOD sites 3Environmental setting of human migrations in the circum-Pacific Region 2
... Spin Kit is an advanced system for isolating DNA ... can be used directly for any downstream application. ... ready to use in 56 minutes Low melting ... TAE and TBE gels No specialised equipment required ...
... The GenElute™ Minus EtBr Spin Columns provide a ... bromide (EtBr)-free DNA (100 bp to 10 kb) ... The DNA band is excised from an agarose ... within the base of the column are a ...
... The Ultra Silica Bead Kit has been designed ... gels and solutions. Features Ultra ... minutes Uniform silica beads are easy to resuspend ... DNA Highly pure DNA (suitable for PCR) ...
... DNA Kit enables efficient extraction of DNA fragments from ... agarose gels. The procedure uses GelMelt solution to dissolve ... to a silica membrane in a spin column format. ... in low-salt buffer. Each spin column can bind up ...
Biology Products: